Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · IEX Real-Time Price · USD
38.46
-0.66 (-1.69%)
At close: Apr 25, 2024, 4:00 PM
39.22
+0.76 (1.98%)
After-hours: Apr 25, 2024, 7:12 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for HALO stock have an average target of 53, with a low estimate of 40 and a high estimate of 72. The average target predicts an increase of 37.81% from the current stock price of 38.46.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HALO stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +30.01% | Apr 17, 2024 |
| Benchmark | Benchmark | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +30.01% | Apr 16, 2024 |
| TD Cowen | TD Cowen | Buy Initiates $54 | Buy | Initiates | $54 | +40.41% | Feb 29, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $72 | Buy | Reiterates | $72 | +87.21% | Feb 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $50 | Strong Buy | Maintains | $48 → $50 | +30.01% | Feb 21, 2024 |
Financial Forecast
Revenue This Year
973.44M
from 829.25M
Increased by 17.39%
Revenue Next Year
1.11B
from 973.44M
Increased by 13.62%
EPS This Year
3.76
from 2.10
Increased by 79.07%
EPS Next Year
4.65
from 3.76
Increased by 23.74%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.0B | 1.2B | 1.4B | 1.8B | 1.7B |
| Avg | 973.4M | 1.1B | 1.3B | 1.6B | 1.5B |
| Low | 924.2M | 1.0B | 1.3B | 1.4B | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.5% | 18.8% | 25.7% | 31.8% | 12.2% |
| Avg | 17.4% | 13.6% | 21.0% | 16.4% | -4.6% |
| Low | 11.5% | 7.5% | 14.6% | 5.3% | -29.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.96 | 4.90 | 6.78 | 8.33 | 10.55 |
| Avg | 3.76 | 4.65 | 6.18 | 6.89 | 7.13 |
| Low | 3.54 | 4.32 | 5.65 | 5.46 | 3.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 88.5% | 30.4% | 45.8% | 34.8% | 53.2% |
| Avg | 79.1% | 23.7% | 32.7% | 11.6% | 3.5% |
| Low | 68.5% | 14.9% | 21.5% | -11.6% | -50.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.